Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future

Malaria is still one of the major killer parasitic diseases in tropical settings, posing a public health threat. The development of antimalarial drug resistance is reversing the gains made in attempts to control the disease. The parasite leads a complex life cycle that has adapted to outwit almost a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Melissa Louise Stofberg, Celine Caillet, Marianne de Villiers, Tawanda Zininga
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	malaria <i>Plasmodium falciparum</i> molecular chaperone heat shock protein 90 Hsp90 inhibitors parasite Hsp90 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/89dad5f8e1934790a56c245e40e2c2b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89dad5f8e1934790a56c245e40e2c2b4
record_format	dspace
spelling	oai:doaj.org-article:89dad5f8e1934790a56c245e40e2c2b42021-11-25T17:07:56ZInhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future10.3390/cells101128492073-4409https://doaj.org/article/89dad5f8e1934790a56c245e40e2c2b42021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2849https://doaj.org/toc/2073-4409Malaria is still one of the major killer parasitic diseases in tropical settings, posing a public health threat. The development of antimalarial drug resistance is reversing the gains made in attempts to control the disease. The parasite leads a complex life cycle that has adapted to outwit almost all known antimalarial drugs to date, including the first line of treatment, artesunate. There is a high unmet need to develop new strategies and identify novel therapeutics to reverse antimalarial drug resistance development. Among the strategies, here we focus and discuss the merits of the development of antimalarials targeting the Heat shock protein 90 (Hsp90) due to the central role it plays in protein quality control.Melissa Louise StofbergCeline CailletMarianne de VilliersTawanda ZiningaMDPI AGarticlemalaria<i>Plasmodium falciparum</i>molecular chaperoneheat shock protein 90Hsp90 inhibitorsparasite Hsp90Biology (General)QH301-705.5ENCells, Vol 10, Iss 2849, p 2849 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	malaria <i>Plasmodium falciparum</i> molecular chaperone heat shock protein 90 Hsp90 inhibitors parasite Hsp90 Biology (General) QH301-705.5
spellingShingle	malaria <i>Plasmodium falciparum</i> molecular chaperone heat shock protein 90 Hsp90 inhibitors parasite Hsp90 Biology (General) QH301-705.5 Melissa Louise Stofberg Celine Caillet Marianne de Villiers Tawanda Zininga Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
description	Malaria is still one of the major killer parasitic diseases in tropical settings, posing a public health threat. The development of antimalarial drug resistance is reversing the gains made in attempts to control the disease. The parasite leads a complex life cycle that has adapted to outwit almost all known antimalarial drugs to date, including the first line of treatment, artesunate. There is a high unmet need to develop new strategies and identify novel therapeutics to reverse antimalarial drug resistance development. Among the strategies, here we focus and discuss the merits of the development of antimalarials targeting the Heat shock protein 90 (Hsp90) due to the central role it plays in protein quality control.
format	article
author	Melissa Louise Stofberg Celine Caillet Marianne de Villiers Tawanda Zininga
author_facet	Melissa Louise Stofberg Celine Caillet Marianne de Villiers Tawanda Zininga
author_sort	Melissa Louise Stofberg
title	Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
title_short	Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
title_full	Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
title_fullStr	Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
title_full_unstemmed	Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
title_sort	inhibitors of the <i>plasmodium falciparum</i> hsp90 towards selective antimalarial drug design: the past, present and future
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/89dad5f8e1934790a56c245e40e2c2b4
work_keys_str_mv	AT melissalouisestofberg inhibitorsoftheiplasmodiumfalciparumihsp90towardsselectiveantimalarialdrugdesignthepastpresentandfuture AT celinecaillet inhibitorsoftheiplasmodiumfalciparumihsp90towardsselectiveantimalarialdrugdesignthepastpresentandfuture AT mariannedevilliers inhibitorsoftheiplasmodiumfalciparumihsp90towardsselectiveantimalarialdrugdesignthepastpresentandfuture AT tawandazininga inhibitorsoftheiplasmodiumfalciparumihsp90towardsselectiveantimalarialdrugdesignthepastpresentandfuture
_version_	1718412725564997632

Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future

Ejemplares similares